Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isocitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | CPT1A | P50416 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isocitric Acid SCHEMBL7188284 | 0.95 | CA4 (0.50) | CA4CTSLCA2SLC22A16LMNA | |
| Isocitric Acid SCHEMBL2583035 | 0.95 | CA4 (0.50) | CA4CTSLCA2SLC22A16LMNA | |
| Isocitric Acid SCHEMBL19138174 | 0.95 | CA4 (0.50) | CA4CTSLCA2SLC22A16LMNA | |
| Isocitric Acid SCHEMBL1061380 | 0.95 | CA4 (0.54) | CA4CTSLCA2SLC22A16LMNA | |
| Isocitric Acid SCHEMBL11648770 | 0.95 | CA4 (0.50) | CA4CTSLCA2SLC22A16LMNA | |
| Isocitric Acid SCHEMBL2396430 | 0.95 | CA4 (0.50) | CA4CTSLCA2SLC22A16LMNA | |
| Isocitric Acid SCHEMBL6739636 | 0.95 | CA4 (0.50) | CA4CTSLCA2SLC22A16LMNA | |
| Isocitric Acid SCHEMBL2581302 | 0.95 | CA4 (0.50) | CA4CTSLCA2SLC22A16LMNA | |
| Isocitric Acid SCHEMBL6739630 | 0.95 | CA4 (0.50) | CA4CTSLCA2SLC22A16LMNA | |
| Isocitric Acid SCHEMBL11483986 | 0.95 | CA4 (0.50) | CA4CTSLCA2SLC22A16LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080160101-A1 | Comprising antagonistic micro-organism and at least one salt and/or derivatives; biopesticide particularly useful against pathogens able to cause diseases to plant material | BIONEXT (BE) | 2008-07-03 | — | — | US | claimed |
| EP-1802196-A1 | COMPOSITIONS FOR USE AGAINST ONE OR MORE PATHOGENS | Bionext (BE) | 2007-07-04 | — | — | EP | claimed |
| WO-2006032530-A1 | COMPOSITIONS FOR USE AGAINST ONE OR MORE PATHOGENS | BIONEXT (BE) | 2006-03-30 | — | — | WO | claimed |
| US-6468779-B1 | PREPARED BY BOILING LEGUMES IN WATER AND REMOVING SOLIDS; MICROBIAL MEDIUM EFFECTIVE FOR PROVIDING AGRONOMICALLY BENEFICIAL MICROBES TO CELL DENSITY OF 108 CELLS/ML; NITROGEN SOURCE, SALT OF ORGANIC ACID, ORGANIC ALCOHOL MAY BE ADDED | TATKO BIOTECH, INC. | 2002-10-22 | — | — | US | claimed |
| JP-57048911-A | — | — | None | — | — | JP | disclosed |
| EP-4689144-A1 | CONSOLIDATED BIOPROCESSING OF COMPLEX CARBOHYDRATES TO D-erythro-ISOCITRIC ACID USING A FUNGUS | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie - Hans-Knöll-Institut - (DE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025096390-A1 | AUTO-EXPRESSION BROTH AND USES THEREOF | UNIVERSITY OF MONTANA (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119791273-A | Probiotic preparation for improving constipation and preparation method thereof | 苏州市中医医院 | 2025-04-11 | — | — | CN | disclosed |
| CN-119174673-A | Traditional Chinese medicine medical instrument system for preventing pressure injury and treating 1-3-stage pressure injury | 张文博 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024199940-A1 | CONSOLIDATED BIOPROCESSING OF COMPLEX CARBOHYDRATES TO D-erythro-ISOCITRIC ACID USING A FUNGUS | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE – HANS-KNÖLL-INSTITUT – (DE) | 2024-10-03 | — | — | WO | disclosed |
| CN-116832125-B | Traditional Chinese medicine composition, preparation method and application thereof | 上海市金山区中西医结合医院 | 2024-08-23 | — | — | CN | disclosed |
| CN-118319813-A | Astaxanthin acne-removing skin care composition and preparation method thereof | 中国热带农业科学院农产品加工研究所 | 2024-07-12 | — | — | CN | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2027956-A1 | PROCESS FOR PRODUCTION OF COLLOIDAL GOLD AND COLLOIDAL GOLD | Tanaka Kikinzoku Kogyo K.K. (JP) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20080160101-A1 | Comprising antagonistic micro-organism and at least one salt and/or derivatives; biopesticide particularly useful against pathogens able to cause diseases to plant material | BIONEXT (BE) | 2008-07-03 | — | — | US | disclosed |
| EP-1802196-A1 | COMPOSITIONS FOR USE AGAINST ONE OR MORE PATHOGENS | Bionext (BE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006032530-A1 | COMPOSITIONS FOR USE AGAINST ONE OR MORE PATHOGENS | BIONEXT (BE) | 2006-03-30 | — | — | WO | disclosed |
| JP-S5748911-A | CARDIOTONIC DRUG | BANYU PHARMACEUT CO LTD | 1982-03-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080160101-A1 | Comprising antagonistic micro-organism and at least one salt and/or derivatives; biopesticide particularly useful against pathogens able to cause diseases to plant material | CHIT1, MAN2A1, MANBA | CA4 1917/4885CTSL 1740/4885CA2 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.